tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

ALT Stock Latest News

Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
The FlyStifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
4d ago
ALT
LLY
Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
The FlyStreet Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
4d ago
ALT
ASO
Altimmune downgraded to Neutral from Buy at Goldman Sachs
The FlyAltimmune downgraded to Neutral from Buy at Goldman Sachs
5d ago
ALT
William Blair says Viking bull thesis intact after Altimmune data
The FlyWilliam Blair says Viking bull thesis intact after Altimmune data
5d ago
ALT
VKTX
Altimmune attractive after ‘overdone’ selloff, says H.C. Wainwright
The FlyAltimmune attractive after ‘overdone’ selloff, says H.C. Wainwright
5d ago
ALT
Altimmune Tanks on Pemvidutide Interim data in Obesity and Type 2 Diabetes
Market NewsAltimmune Tanks on Pemvidutide Interim data in Obesity and Type 2 Diabetes
5d ago
ALT
Altimmune’s Pemvi ‘at least as good’ as semaglutide, says JMP Securities
The FlyAltimmune’s Pemvi ‘at least as good’ as semaglutide, says JMP Securities
5d ago
ALT
Altimmune announces reuslts from interim analysis of MOMENTUM Phase 2 trial
The FlyAltimmune announces reuslts from interim analysis of MOMENTUM Phase 2 trial
5d ago
ALT
Altimmune put volume heavy and directionally bearish
The FlyAltimmune put volume heavy and directionally bearish
6d ago
ALT
Altimmune call volume above normal and directionally bullish
The FlyAltimmune call volume above normal and directionally bullish
17d ago
ALT
Altimmune call volume above normal and directionally bullish
The FlyAltimmune call volume above normal and directionally bullish
18d ago
ALT
Altimmune call volume above normal and directionally bullish
The FlyAltimmune call volume above normal and directionally bullish
23d ago
ALT
B. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates
The FlyB. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates
26d ago
ALT
Altimmune reports Q4 EPS (43c), consensus (50c)
The FlyAltimmune reports Q4 EPS (43c), consensus (50c)
26d ago
ALT
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Press ReleasesAltimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
26d ago
ALT
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
Press ReleasesAltimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
1M ago
ALT
3 Stocks to Buy Today, 2/14/2023, According to Top Analysts
Stock Analysis & Ideas3 Stocks to Buy Today, 2/14/2023, According to Top Analysts
1M ago
ALT
ANET
JMPS Securities biotech analysts hold an analyst/industry conference call
The FlyJMPS Securities biotech analysts hold an analyst/industry conference call
1M ago
ALT
JMPS Securities biotech analysts hold an analyst/industry conference call
The FlyJMPS Securities biotech analysts hold an analyst/industry conference call
1M ago
ALT
JMPS Securities biotech analysts hold an analyst/industry conference call
The FlyJMPS Securities biotech analysts hold an analyst/industry conference call
2M ago
ALT
Guggenheim views Altimmune risk/reward heading into MOMENTUM as attractive
The FlyGuggenheim views Altimmune risk/reward heading into MOMENTUM as attractive
2M ago
ALT
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analyst to hold analyst/industry conference call
2M ago
ALT
TAK
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analyst to hold analyst/industry conference call
2M ago
ALT
TAK
Altimmune management to meet virtually with Piper Sandler
The FlyAltimmune management to meet virtually with Piper Sandler
2M ago
ALT
Altimmune management to meet virtually with Piper Sandler
The FlyAltimmune management to meet virtually with Piper Sandler
2M ago
ALT
Altimmune price target raised to $25 from $14 at Evercore ISI
The FlyAltimmune price target raised to $25 from $14 at Evercore ISI
2M ago
ALT
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analyst to hold analyst/industry conference call
2M ago
ALT
TAK
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
Press ReleasesAltimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
3M ago
ALT
Altimmune Appoints Raymond Jordt as Chief Business Officer
Press ReleasesAltimmune Appoints Raymond Jordt as Chief Business Officer
3M ago
ALT
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.